文献速递神经肿瘤

放线菌素D下调Sox2并改善复发性胶质母细胞瘤临床前模型的生存

Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma.
PubMed 文献 · Neuro Oncol · 2020-01-01

研究利用12例患者来源的胶质瘤干细胞样细胞系在多细胞球体中进行高通量筛选,从133种FDA批准化合物中鉴定出放线菌素D具有高度细胞毒性,并在2个复发性胶质母细胞瘤患者来源模型中验证其可显著缩小肿瘤、延长生存,同时在体外和体内特异性下调Sox2表达。

要点

  • 高通量筛选从133种FDA批准化合物中鉴定出放线菌素D对12例患者来源胶质瘤干细胞样细胞系具有高度细胞毒性。
  • 放线菌素D在2个复发性胶质母细胞瘤患者来源模型中显著缩小肿瘤并显著延长生存。
  • 放线菌素D在体外和体内均特异性下调干细胞转录因子Sox2的表达。

核心结论

  • 研究结果表明,正如高通量筛选所预测,放线菌素D可能耗竭肿瘤内的癌症干细胞群,最终导致肿瘤进展延迟。

研究设计与样本

  • 研究将12例患者来源的胶质瘤干细胞样细胞系以多细胞球体形式在无血清384孔板中于10 µM浓度下对133种FDA批准化合物进行筛选。
  • 随后在体外以已确定的半数抑制浓度(IC50)用放线菌素D处理胶质瘤干细胞样细胞,并通过蛋白质印迹和鼠脑组织免疫组织学评估Sox2下调。
  • 研究还在3维胶质瘤干细胞样细胞培养和复发性胶质母细胞瘤患者来源异种移植模型中验证放线菌素D。

主要发现

  • 高通量筛选系统鉴定出放线菌素D对12例患者来源胶质瘤干细胞样细胞系具有高度细胞毒性。
  • 放线菌素D在2个复发性胶质母细胞瘤患者来源模型中显著缩小肿瘤并显著延长生存。
  • 放线菌素D在体外和体内均特异性下调Sox2表达。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) has been extensively researched over the last few decades, yet despite aggressive multimodal treatment, recurrence is inevitable and second-line treatment options are limited. Here, we demonstrate how high-throughput screening (HTS) in multicellular spheroids can generate physiologically relevant patient chemosensitivity data using patient-derived cells in a rapid and cost-effective manner. Our HTS system identified actinomycin D (ACTD) to be highly cytotoxic over a panel of 12 patient-derived glioma stemlike cell (GSC) lines. ACTD is an antineoplastic antibiotic used in the treatment of childhood cancers. Here, we validate ACTD as a potential repurposed therapeutic for GBM in 3-dimensional GSC cultures and patient-derived xenograft models of recurrent glioblastoma. METHODS: Twelve patient-derived GSC lines were screened at 10 µM, as multicellular spheroids, in a 384-well serum-free assay with 133 FDA-approved compounds. GSCs were then treated in vitro with ACTD at established half-maximal inhibitory concentrations (IC50). Downregulation of sex determining region Y-box 2 (Sox2), a stem cell transcription factor, was investigated via western blot and through immunohistological assessment of murine brain tissue. RESULTS: Treatment with ACTD was shown to significantly reduce tumor growth in 2 recurrent GBM patient-derived models and significantly increased survival. ACTD is also shown to specifically downregulate the expression of Sox2 both in vitro and in vivo. CONCLUSION: These findings indicate that, as predicted by our HTS, ACTD could deplete the cancer stem cell population within the tumor mass, ultimately leading to a delay in tumor progression. KEY POINTS: 1. High-throughput chemosensitivity data demonstrated the broad efficacy of actinomycin D, which was validated in 3 preclinical models of glioblastoma.2. Actinomycin D downregulated Sox2 in vitro and in vivo, indicating that this agent could target the stem cell population of GBM tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Taylor JT, Ellison S, Pandele A, et al. Actinomycin D downregulates Sox2 and improves survival in preclinical models of recurrent glioblastoma. Neuro Oncol. 2020. PMID: 32227096. doi:10.1093/neuonc/noaa051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。